Compare YHGJ & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | NXL |
|---|---|---|
| Founded | 1975 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | 2006 | 2022 |
| Metric | YHGJ | NXL |
|---|---|---|
| Price | $2.70 | $5.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.4K | ★ 2.3M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,705,000.00 | $301,647.00 |
| Revenue This Year | N/A | $14.37 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.76 | ★ 78.78 |
| 52 Week Low | $2.38 | $0.22 |
| 52 Week High | $10.29 | $10.98 |
| Indicator | YHGJ | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 58.20 |
| Support Level | $2.61 | $0.36 |
| Resistance Level | $3.09 | $7.69 |
| Average True Range (ATR) | 0.17 | 0.79 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 48.16 | 21.78 |
Yunhong Green CTI Ltd develops, produces, distributes, and sells consumer products in the United States and several other countries, and manufactures film products for commercial and industrial use in the United States. The Company focuses on flexible film technologies and has developed products utilizing flexible films, including novelty balloons, pouches, and films for packaging applications. Its principal product lines include foil and latex balloons and related gift items, and flexible films for food and other packaging uses. It also assembles balloon-inspired gift items, including small gift bouquets with ribbons and/or a foil balloon, and holds patents related to flexible films, including films, zipper closures, valves, and other features.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.